- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04801433
Evaluate the Efficacy and Safety of Boroda Supramolecular Active Zinc in the Treatment of Scalp Psoriasis
A Multicenter, Randomized, Single-blind, Parallel-controlled Clinical Study to Evaluate the Efficacy and Safety of Boroda Supramolecular Active Zinc in the Treatment of Scalp Psoriasis
A multicenter, randomized, single-blind, parallel-controlled clinical study to evaluate the efficacy and safety of boroda supramolecular active zinc in the treatment of scalp psoriasis.
Main objective::Compare the efficacy of boroda supramolecular active zinc and capotetriol liniment in the treatment of scalp psoriasis Secondary objective: To observe the safety of boroda supramolecular active zinc in the treatment of subjects with scalp psoriasis
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Dermatology Derpartment of Xijing Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18-65,regardless of gender;
Clinically diagnosed as scalp psoriasis and severity of the disease:
- According to the researchers evaluation of clinical signs, each of the three clinical signs of scalp psoriasis, erythema, infiltration and scales, needs to be < 3 points, and at least one sign score is ≥ 1.
- <25% of the total scalp area (the fully expanded flat palm (including the surface of five fingers) is equivalent to approximately 25% of the scalp area).
- The judgment of mild to moderate outcome need to be in accordance with the overall evaluation criteria;
- At the time of admission, the skin lesions of the body and limbs of the subjects need to have clinical signs of psoriasis vulgaris (the maximum surface of the affected area is ≤10%) or had been diagnosed as psoriasis vulgaris on the body and limbs at the early stage.
- Subjects must sign a informed consent of notification in prior to the study;
Exclusion Criteria:
- Subjects are diagnosed with active guttate psoriasis, pustular psoriasis, arthropathy psoriasis and erythroderma psoriasis at present.
- The subjects scalp associated with other diseases that may affect the judgment of curative effect: such as, viral infection, fungal infection, bacterial infection, parasitic infection, skin manifestations associated with syphilis or tuberculosis, rosacea, acne, post-acne inflammation, skin atrophy, atrophic stria, increased skin venous vulnerability, ichthyosis, ulcer or wound that skin manifestations related to injury;
- Any infectious skin disease that confuses the evaluation of the efficacy of scalp psoriasis
- The subjects that had received systemic biotherapy (listed or not listed) in the past three months of randomized enrollment that may have potential effects on scalp psoriasis, such as alefaxer, legalizumab, etanercept, infliximab, etc.
- The subjects who had received non-biological systemic therapies that may have an impact on scalp psoriasis, such as corticosteroids, vitamin D-type drugs, Tretinoin, immunosuppressive agents, etc. in 4 weeks before the 2nd screening visit or during the study period.
- Randomly enrolled (1st visit) subjects who have received PUVA treatment 4 weeks before or during the study period;
- Randomly enrolled (1st visit) subjects that had received ultraviolet therapy 2 weeks before or during the study period;
The subjects that had received the following treatments 2 weeks before the 2nd screening or during the study period:
- Strong or extremely effective steroid hormone external preparations for psoriasis on the body and limbs (WHO Class III-IV);
- External immunomodulators (such as tacrolimus ointment, etc.)
- External use of vitamin D analogues (e.g. captopril preparation, tacalcitol and calcitriol);
- External treatment of various types of scalp psoriasis (except for shampoos or softeners that are not steroid drugs);
- Other treatments for psoriasis: such as traditional Chinese medicine or Chinese patent medicine, hot springs, etc.
- During the study period, it is planned to start or change the use of concomitant drugs that may affect scalp psoriasis, such as beta-blockers, antimalarials, lithium preparations, etc.
- Subjects who are known or suspected to be allergic to the drug components in the study;
- Pregnant or fertile female intend to be pregnant or lactating during the study period;
- In the 2nd screening visit, the serum or urine pregnancy test of fertile women is positive.
- The subjects who participated in other clinical trials within 4 weeks of randomization;
- The subjects with known or suspected poor compliance who could not complete the tests, such as alcoholism, drug dependence or mental illness, or the subjects who are not suitable to participate in this clinical research that determined by the researchers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Boleda Supramolecular Active Zinc
Boleda Supramolecular Active Zinc (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle.
Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
|
Boleda Supramolecular Active Zinc Conditioner (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle.
Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
|
Active Comparator: Capotetriol scalp solution
30ml/bottle.
Two times a day for 4 weeks, topically applied to scalp psoriasis.
|
Capotetriol scalp solution: 30ml/bottle.
Two times a day for 4 weeks, topically applied to scalp psoriasis.
|
Placebo Comparator: Supramolecular Hydrogel
30ml/bottle.
Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
|
Supramolecular Hydrogel (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle.
Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Success rate at the end of treatment (4th week) in each group (percentage of patients with overall score of < 1)
Time Frame: Change of success rate from baseline at 4 weeks
|
The overall criteria for assessing the severity of disease for researchers are a static skin scoring system consisting of six levels (score of 0-5) of change from "disappearance" to "very serious" diseases. The main endpoint of the overall assessment criteria for disease severity according to the researchers will be "disease control", defined as "disappearance (score of 0) " or "extreme mild (score of 1) " disease grade at the end of treatment. At the end of treatment, the proportion of the subjects who are evaluated as disease under control (signs disappeared and extremely mild) by "the overall assessment of the severity of disease by researchers" base on observation. Comparing the disease control rates among the groups can reflect the differentiation treatment efficacy. |
Change of success rate from baseline at 4 weeks
|
The clinical signs of psoriasis (erythema, infiltration, and scaly) (The Total sign score (TSS))
Time Frame: Change of sclinical signs of psoriasis from baseline at 4 weeks
|
Scoring each symptom once on the basis of the five-point system given below can assess the average severity of all scalp lesions. 0 = no sign
At the end of treatment, researchers need to evaluate scalp psoriasis in all subjects from three aspects: erythema, infiltration and scales. The percentage of remission per clinical sign (erythema, infiltration, scales) in each group (percentage of patients with clinical score = 0). |
Change of sclinical signs of psoriasis from baseline at 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation criteria of pruritus symptoms in the subjects
Time Frame: Change of spruritus symptoms from baseline at 4 weeks
|
At the end of treatment, the subject are assessed for the severity of the disease according to the four-level system presented below. Researchers should explain the grading criteria to patients, and the subjects should judge the grading and tick it.
|
Change of spruritus symptoms from baseline at 4 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XijingH-PF-Pso-2018/2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scalp Psoriasis
-
Janssen Research & Development, LLCActive, not recruitingPlaque Psoriasis | Scalp PsoriasisUnited States, Canada
-
Paul Steven Yamauchi, MD, PhDJanssen Services, LLCUnknownA Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp PsoriasisPlaque Psoriasis | Scalp PsoriasisUnited States
-
Arcutis Biotherapeutics, Inc.CompletedScalp PsoriasisUnited States, Canada
-
Glenmark Pharmaceuticals Ltd. IndiaCompleted
-
Taro Pharmaceuticals USACompleted
-
Tolmar Inc.CompletedScalp PsoriasisUnited States
-
LEO PharmaCompleted
-
LEO PharmaCompletedScalp PsoriasisCanada, United Kingdom, France
-
Dermatology Consulting Services, PLLCOrtho DermatologicsCompletedScalp PsoriasisUnited States
-
Jinnah Postgraduate Medical CentreCompleted
Clinical Trials on Boleda Supramolecular Active Zinc Conditioner
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityCompleted
-
Mackay Memorial HospitalCompleted
-
Adeona PharmaceuticalsUnknownMild Cognitive Impairment | Alzheimer's DiseaseUnited States
-
Greet Van den BergheFund for Scientific Research, Flanders, Belgium; Agency for Innovation by Science...Completed
-
Rabin Medical CenterSanofiTerminated
-
National University Hospital, SingaporeCompleted
-
Church & Dwight Company, Inc.Completed